| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 06/13/2001 | EP1105140A2 Benzothiepine compounds as enhancer of cell differentiation induction factor |
| 06/13/2001 | EP1105139A1 Ophthalmic solution with tetracycline for topical treatment of dry eye disease |
| 06/13/2001 | EP1105138A1 Chromium polynicotinate compositions and uses thereof |
| 06/13/2001 | EP1105137A1 Chromium picolinate compositions and uses thereof |
| 06/13/2001 | EP1105136A2 Method for treating ocular neovascular diseases |
| 06/13/2001 | EP1105135A1 Antiviral indoleoxoacetyl piperazine derivatives |
| 06/13/2001 | EP1105134A2 Nalmefene in combination with opioid analgesics |
| 06/13/2001 | EP1105133A1 Tricyclic compounds |
| 06/13/2001 | EP1105132A1 The use of r(+)-g(a)-(2,3-dimethoxyphenyl)-1- 2-(4-fluorophenyl)ethyl]-4-piperidinemethanol for the treatment of sleep disorders |
| 06/13/2001 | EP1105131A2 Small molecule carbamates or ureas for vision and memory disorders |
| 06/13/2001 | EP1105130A2 Heterocyclic esters or amides for vision and memory disorders |
| 06/13/2001 | EP1105129A1 Amelioration of apomorphine adverse effects |
| 06/13/2001 | EP1105128A2 Carboxylic acids and isosteres of n-heterocyclic compounds for vision and memory disorders |
| 06/13/2001 | EP1105127A1 Treatment of fecal incontinence |
| 06/13/2001 | EP1105126A2 Sulfonamides of n-containing heterocyclic thioesters for vision and memory disorders |
| 06/13/2001 | EP1105125A2 Use of sulfonamides for treating vision and memory disorders |
| 06/13/2001 | EP1105124A2 N-linked sulfonamides of n-heterocyclic carboxylic acids or isosteres for vision and memory disorders |
| 06/13/2001 | EP1105123A1 Pharmaceutical compositions containing lipase inhibitors and chitosan |
| 06/13/2001 | EP1105122A1 Pharmaceutical compositions containing lipase inhibitors |
| 06/13/2001 | EP1105121A1 Ascorbate-isoquercetin compositions |
| 06/13/2001 | EP1105120A2 NON-PEPTIDE GnRH AGENTS, METHODS AND INTERMEDIATES FOR THEIR PREPARATION |
| 06/13/2001 | EP1105119A2 New use of taxoid derivatives |
| 06/13/2001 | EP1105117A1 Bio-chemical germanium complexes with high therapeutic efficiency and wide application spectrum |
| 06/13/2001 | EP1105116A1 Hydroxamic acid derivatives as inhibitors of beta-amyloid production |
| 06/13/2001 | EP1105115A1 Enhancement of exercise performance by augmenting endogenous nitric oxide production or activity |
| 06/13/2001 | EP1105114A1 Nimesulide containiing topical pharmaceutical compositions |
| 06/13/2001 | EP1105113A1 Composition and method for treating peyronie's disease and other sub-dermal plaque manifestation disorders |
| 06/13/2001 | EP1105112A2 Compositions and uses for vision and memory disorders |
| 06/13/2001 | EP1105111A1 Transdermally administered tolterodine as anti-muscarinic agent for the treatment of overactive bladder |
| 06/13/2001 | EP1105109A1 Injectable formulations of nanoparticulate naproxen |
| 06/13/2001 | EP1105105A1 Oral administration form for pyridin-2-ylmethylsulfinyl-1h-benzimidazoles |
| 06/13/2001 | EP1105104A1 Extended release buccal bioadhesive tablet |
| 06/13/2001 | EP1105102A1 Pharmaceutical composition for injection based on a pharmaceutically acceptable clopidogrel or ticlopidin salt |
| 06/13/2001 | EP1105101A2 Compositions and methods for treating intracellular infections |
| 06/13/2001 | EP1105098A1 Liposomal bupivacaine compositions prepared using an ammonium sulfate gradient |
| 06/13/2001 | EP1105097A2 Targeted vesicular constructs for cytoprotection and treatment of h.pylori infections |
| 06/13/2001 | EP1105096A1 Injectable aqueous dispersions of propofol |
| 06/13/2001 | EP1105094A1 Methods for forming regional tissue adherent barriers and drug delivery systems |
| 06/13/2001 | EP1105002A2 Carbohydrates mixture |
| 06/13/2001 | EP1007021B1 Transdermal, oral and intravenous preparations of 2,3-dimethoxy-5-methyl-6-decaprenyl-1,4-benzoquinone |
| 06/13/2001 | EP0967975B1 Fluoroether compositions and methods for inhibiting their degradation in the presence of a lewis acid |
| 06/13/2001 | EP0958354A4 Thiomethylene group-containing aldehyde cysteine and serine protease inhibitors |
| 06/13/2001 | EP0944571B1 Asiatic acid derivatives having modified a-ring |
| 06/13/2001 | EP0927029A4 Novel methods |
| 06/13/2001 | EP0888289B1 Anticonvulsant enantiomeric amino acid derivatives |
| 06/13/2001 | EP0877598B1 Anthelmintic paste |
| 06/13/2001 | EP0863870B1 Sulfur containing di-tert-butylphenol compounds useful as anti-inflammatory agents |
| 06/13/2001 | EP0859615B1 Carbostyril derivative for curing ophthalmological diseases |
| 06/13/2001 | EP0854875B1 New cephem compounds |
| 06/13/2001 | EP0842143B1 2-(4-substituted)-benzylamino-2-methyl-propanamide derivatives |
| 06/13/2001 | EP0824527B1 Quinazoline derivatives |
| 06/13/2001 | EP0824526B1 Quinazoline derivative |
| 06/13/2001 | EP0824525B1 Quinazoline derivatives |
| 06/13/2001 | EP0820432B1 Esters of 5-aminolevulinic acid as photosensitizing agents in photochemotherapy |
| 06/13/2001 | EP0807101B1 2-aminoindans as selective dopamine d3 ligands |
| 06/13/2001 | EP0805858B1 Inhibition of neovascularization using vegf-specific oligonucleotides |
| 06/13/2001 | EP0805812B1 Bicyclic substituted hexahydrobenz(e)isoindole alpha-1- adrenergic antagonists |
| 06/13/2001 | EP0797432B1 Oil-in-water emulsions |
| 06/13/2001 | EP0789562B1 Sustained release caffeine formulation |
| 06/13/2001 | EP0781279B1 Quinoxalinedione nmda receptor antagonists |
| 06/13/2001 | EP0755382B1 Quinolone derivative for treatment of urinary incontinence |
| 06/13/2001 | EP0741722B1 Triazole derivatives |
| 06/13/2001 | EP0727990B1 Compounds, compositions and treatment of allergies and inflammation |
| 06/13/2001 | EP0710103B1 Pharmaceutical compositions for hardly soluble active substances |
| 06/13/2001 | EP0690864B1 Crystalline ceftiofur free acid |
| 06/13/2001 | EP0688331B1 New sulfated lyso-ganglioside derivatives |
| 06/13/2001 | EP0687174B1 Crystalline cyclodextrin inclusion complexes of ranitidine hydrochloride and process for their preparation |
| 06/13/2001 | EP0686034B1 Bisacodyl dosage form |
| 06/13/2001 | EP0678019B1 Enhanced solubility pharmaceutical solutions |
| 06/13/2001 | EP0666858B1 5-arylindole derivatives and their use as serotonin (5-ht 1) agonists |
| 06/13/2001 | DE19959917A1 Hydroxyether Hydroxyethers |
| 06/13/2001 | DE19959119A1 Emulsionen Emulsions |
| 06/13/2001 | DE19958985A1 Oligosaccharidmischung Oligosaccharide |
| 06/13/2001 | DE19957371A1 Mitomycin C-Lösung Mitomycin C solution |
| 06/13/2001 | DE19956400A1 Cholesterol-lowering cardioprotective and vasoprotective composition comprises conjugated linoleic acids and omega-3 fatty acids |
| 06/13/2001 | CN1299414A Compound and method for therapy and diagnosis of lung cancer |
| 06/13/2001 | CN1299410A CD 19XCD2 specific polypeptides and uses thereof |
| 06/13/2001 | CN1299368A Improvement in macrolide prodn. |
| 06/13/2001 | CN1299367A 2''-deoxy hygromycin derivatives |
| 06/13/2001 | CN1299366A 5-imino-13-doxy anthracycline derivatives, their uses, and processes for preparing them |
| 06/13/2001 | CN1299365A Hygromycin A derivatives |
| 06/13/2001 | CN1299361A Hypnotic beta-carboline derivatives, process for their prepn. and their use as medicinal products |
| 06/13/2001 | CN1299359A Benzofurylpyrone derivatives |
| 06/13/2001 | CN1299358A Heterocyclic Topoisomerase poisons |
| 06/13/2001 | CN1299357A Indole derivatives useful A.O. for the treatment of osteoporosis |
| 06/13/2001 | CN1299350A Substituted 11-phenyl-dibenzazepine compounds useful for the treatment or prevention of disease characterized by abnormal cell proliferation |
| 06/13/2001 | CN1299348A SPLA inhibitor compounds for treatment of disease |
| 06/13/2001 | CN1299347A Inhibitor of phospholipase enzymes |
| 06/13/2001 | CN1299346A Ureas and carbamates of N-heterocyclic carboxylic acids and carboxylic acid isosteres |
| 06/13/2001 | CN1299343A Biphenyl derivatives |
| 06/13/2001 | CN1299342A Aliphatic amino carboxylic and amino phosphonic acids, amino nitriles and amino tetrazoles as cellular rescue agents |
| 06/13/2001 | CN1299283A Composition comprising L-carnitine or an alkanoyl L-carnitine and NADH and/or NADPH |
| 06/13/2001 | CN1299282A Vitronectin receptor antagonists |
| 06/13/2001 | CN1299281A Use of oxazolidinone derivative for treating psoriasis, arthritis and reducing the toxicity of cancer chemotherapy |
| 06/13/2001 | CN1299280A Indoly-1-3-glyoxylic acid derivatives with antitumoral activity |
| 06/13/2001 | CN1299279A Use of nicotinic receptor agonist |
| 06/13/2001 | CN1299278A Inhibition of angiogenesis |
| 06/13/2001 | CN1299277A Pharmaceutical compositions contg. the phospholipase inhibitor sodium [[3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy] acetate |
| 06/13/2001 | CN1299276A CYP2A enzymes and their use in therapeutic and diagnostic method |
| 06/13/2001 | CN1299275A Drugs for reducing vaginal acidity and treatment of vaginitis, and the use thereof |